• Home
  • About Us
    • Overview
    • R&D Facilities
    • Management Team
  • Antibiotic Resistance
  • Lead Product
  • R&D Facilities
  • News
  • Contact Us
    • Contact Us
    • Careers
logo
  • Home
  • About Us
    • Overview
    • R&D Pipeline
    • Leadership Team
  • Antibiotic Resistance
  • Lead Products
    • Lysigen
    • Phagelux
  • R&D Facilities
  • News
  • Contact Us
    • Contact Us
    • Careers
En
  • En
  • 中文

News

Home News
  • Phagelux Subsidiary Company Name Change to Lysigen

    Shanghai, Wuhan, November 12, 2021: Phagelux, Inc. is proud to announce the change of name of its Wuhan-based subsidiary to Lysigen (Chinese Name).
    2021-11-12
  • Phagelux Staph Lysin Out-licensing Announcement

    Montreal, Shanghai, Wuhan, November 4, 2021: Phagelux, Inc. is proud to announce the out-licensing of its staphylococcus lysin to Shanghai Pharmaceutical Holdings Co. (hereinafter referred to as “SPH”, 601607.SH; 2607.HK) for in vivo applications. This licensing agreement is limited to the greater China market.
    2021-11-04
  • LysiThru™ Public Announcement

    Montreal, Shanghai, Wuhan, October 11, 2021: Phagelux, Inc. is proud to announce the trademark filing of LysiThru, our novel high through put screening system for rapidly developing lysins effective against both gram positive and gram negativebacteria.
    2021-10-11
  • Phagelux CEO Mark Engel interviewed at JP Morgan Conference

    Jan.16, 2020 Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.
    2020-01-06
  • Home
  • About Us
    • Overview
    • R&D Pipeline
    • Leadership Team
  • Antibiotic Resistance
  • Lead Products
    • Lysigen
    • Phagelux
  • R&D Facilities
  • News
  • Contact Us
    • Contact Us
    • Careers

Copyright 2021-2022  PrecisioBiotix

Copyright © PrecisioBiotix support: 极速建站